A series of isatin-3-ylidene (6a-i) and arylthiazolyl-1,3,4-oxadiazole-2-thione derivatives 7a-i derived from arylthiazolyl carbohydrazide analogs 4a-i were synthesized. Analogously, coupling of 4f with various amino acid methyl esters in the presence of HOBt/DCC reagents afforded the carboxamide derivatives 9a-d. The newly synthesized compounds were assayed against HIV-1 and HIV-2 in MT-4 cells. All compounds are inactive, except compounds 9b and 9c which showed inhibition of HIV-1 with EC 50 = 2.34 µg mL −1 , and 1.12 µg mL −1 with therapeutic indexes (SI) of 9 and <1, respectively.
Introduction
Acquired immune deficiency syndrome (AIDS) is one of the major causes of death in many countries of the world. This viral disease is caused by the retrovirus HIV-1 (human immunodeficiency virus type-1), a retrovirus of the lentivirus family. Integrase, reverse transcriptase and protease (the three viral enzymes) play a prominent role in the virus replication cycle. The formation of proviral DNA from viral RNA is catalyzed by viral reverse transcriptase (RT) and is responsible for viral replication [1] , hence it is the main target in contemporary drug discovery against HIV-1 [2] . Numerous classes of nonnucleoside reverse transcriptase inhibitors (NNRTIs) such as nevirapine [3] , delaviridine [4] and efavirenz (EFV) [5] , carrying a heterocyclic backbone, have been approved for the treatment of HIV infection [6] , due to their unique antiviral potency, high specificity and low toxicity [7, 8] . New types of NNRTIs are continuously being developed, for example some 2,5-disubstituted 1,3,4-oxadiazoles [9 -11] and certain adamantane derivatives [12] have been reported to show anti-HIV activity. In addition, the 1,3,4-oxadiazole ring is of significant interest due to its chemotherapeutic history [13 -15] .
A series of thiazolylthioureas has exhibited activity against two NNRTI resistant HIV-1 isolates [2] . Thiazolidene benzenesulfonamides have inhibited HIV-1 replication and exhibited potent activity against the WT and Y181C RT and to a lesser extent against the K103N RT [16] . Moreover, thiazoles serve as important pharmacodynamic nuclei, and their incorporation in different heterocyclic scaffolds results in varied biological activities such as antitumor [17] , anticonvulsant [18] , antimicrobial [19 -22] , anti-inflammatory [23] , antiprotozoal [24] , and antityrosinase [25] . Furthermore, some amino acid derivatives such as the lysyl amide prodrug of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole [26] , amino acid derivatives of paclitaxol [27] , pyroglutamic acid [28] , cysteine-modifying agents [29] , and isoquinoline carboxylic acid derivatives [30] were reported as potential HIV protease inhibitors [31] . Recently, Al-Masoudi et al. [32 -36] have reported the synthesis of various naphthalene, coumarin and sebacoyl derivatives bear-ing amino acid moieties as potential anti-HIV candidates.
In the present study, we selected 2-aryl-1,3-thiazole-4-carbohydazide intermediates, of which some analogs have been reported previously [37] , for the synthesis of 1,3,4-oxadiazole-2-thiones, their 1,2,4-triazole, isatin-3-ylidene and carboxamide derivatives and for the evaluation of their anti-HIV activiy.
Results and Discussion

Synthesis
The synthesis of the target compounds was accomplished starting from arylthioamides 1a-i, by treatment with ethyl bromopyruvate to give ethyl 2-aryl-1,3-thiazole-4-carboxylates 2a-i, which were used directly without purification by treatment with hydrazine hydrate to furnish the corresponding carbohydrazide analogs 4a-i in 68 % -79 % yield. The carbohydrazides 4a-i were used as common precursors for the synthesis of various potential analogs. Thus, treatment of 4a-i with isatin (5) afforded the isatin-3-ylidene derivatives in 68 % -74 % yield. Analogously, reaction of 4a-i with CS 2 in refluxing MeOH led to the cyclization of the carbohydrazide backbones, furnishing 5-(2-aryl-1,3-thiazol-4-yl)-1,3,4-oxadiazole-2-thione analogs 6a-i (65 % -75 % yield). The reaction sequence is summarized in Scheme 1. The structures of 4a-i, 6a-i and 7a-i were assigned on the basis of IR, 1 H, 13 C NMR and mass spectra. The IR spectra of 7a-i showed strong absorptions in the range of 1241 -1202 cm −1 , attributed to the C=S group. In the 1 H NMR spectra of 4a-i, the singlets in the region δ = 8.09 -8.42 ppm were attributed to 5-H of the thiazole backbone. Proton 5-H of the isatin-3-ylidene (6a-i) and oxadiazole (7a-i) derivatives appeared in the regions δ = 8.60-8.86 and 8.68 -8.86 ppm with chemical shift differences of ∼ 0.45 and ∼ 0.35 ppm, respectively, from those of carbohydrazides 4a-i. The 13 C NMR spectra of 4a-i, 6a-i and 7a-i were assigned (cf. Experimental Section) based on the analysis made for 7f. The spectrum showed a down-field signal at δ = 177.7 ppm, attributed to the C=S group, which is indicative of 7f existing predominantly in the thione form, as is also suggested by the IR and 1 H NMR spectra. The resonances at δ = 164.9 and 156.9 ppm were assigned to C-4 and C-5 of the thiazole and oxadiazole residues, respectively. The signals at δ = 138.9 and 137.6 ppm were assigned to C-4 and C-1 of the thiazole and the aromatic ring, respectively. The aromatic C(4)-Cl and C(2)-Cl carbon atoms gave signals at δ = 137.6 and 131.4 ppm, respectively, and C-4, C-3, C-6, and C-2 appeared at δ = 131.1, 130.6, 128.9, and 126.4 ppm, respectively. Next, our target was the synhesis of new compounds having a thiazole backbone adjacent to an amino acid precursor via an amide linkage, aiming to evaluate their anti-HIV activity. The hydrazide 4f was selected as starting material for the reaction with appropriate acylated amino acids, via the azide-coupling method. Thus, treatment of 4f at −5 • C in HOAc and 1 N HCl with NaNO 2 , followed by the treatment of in situ-generated azide derivative 8 with the acylated amino acid derivatives (glycine, L-serine, Lmethionine, L-alanine and L-valine acetates) in ethyl acetate containing Et 3 N at 0 • C gave, after neutralization, the desired carboxamides 9a-d in 65 % -77 % yield (Scheme 2).
The structures of 9a-e were assigned from their 1 H and 13 C NMR, and mass spectra. The 1 H NMR spectra of 9a-e showed a similar pattern of 1,3-thiazole protons. The low-field broad singlets (δ = 9.95 -9.76 ppm) were assigned to NH signals, and the singlets in the range δ = 9.20 -9.09 ppm were assigned to 5-H of the thiazole backbone. The C-8 methylene protons of 9a appeared as a doublet at δ = 4.19 ppm (J = 2.2 Hz), whereas 8-H atoms of 9b-e resonated as multiplets at δ = 4.36, 4.39, 4.29, and 4.32 ppm, respectively. In the 13 C NMR spectra of 9a-e, the carbon atoms of the carboxylate groups resonated in the range δ = 173.2 -170.2 ppm, and C-2 and C-4 of the thiazole residues appeared in the ranges δ = 168.3-167.1 and 150.1 -148.7 ppm, respectively. The carbonyl groups adjacent to the thiazole precursor, C(6)=O, resonated at δ = 162.7 -160.9 ppm. The resonances at δ = 38.2, 55.2, 52.2, 49.3 and 54.2 ppm were attributed to the C-8 atoms. The CH 2 OH carbon signal of 9b appeared at δ = 59.5 ppm, while the CH 2 S carbon atom of 9c resonated at δ = 30.1 ppm and the CH 2 CH 2 S carbon atom at δ = 32.2 ppm. Compound 9d was selected for further HMBC NMR studies [38] . A gradient-selected HMBC spectrum allowed the identification of C(4) and C(2) of the thiazole ring at δ = 167.7 and 149.8 ppm, respectively, from the 2 J C,H and 3 J C,H correlations to 5-H of the thiazole backbone at δ = 9.12 ppm. Similarly, the CH 3 signal at δ = 19.6 ppm and C-6 of the carbonyl group at δ = 162.7 ppm were identified from their 2 J C,H and 3 J C,H correlations to 8-H at δ = 4.29 ppm (Fig. 1) . The mass fragmentation patterns were consistent with the suggested structures; however, the FAB-MS spectra showed the protonated molecular ions of these compounds.
In-vitro anti-HIV assay
Compounds 6a-i, 7a-i and 9a-e were evaluated for their in vitro anti-HIV activity by using the IIIB strain for HIV-1 and the ROD strain for HIV-2 in human T-lymphocyte (MT-4) cells. Cytotoxicity induced by these compounds was also measured in MT-4 cells parallel with the antiviral activity. The results are summarized in Table 1 , in which the data for Nevirapine (BOE/BIRG587) [39] and azidothymidine (AZT) [40] , are included for comparison. All the compounds are inactive except for 9a and 9b which showed EC 50 = 2.34 µg mL −1 (SI = 9) and 1.12 µg mL −1 (SI ≤ 1), respectively, for which the data can be discussed. However, none of our compounds approached the activity level of the reference compounds.
Compounds 9b and 9c are equipotent against HIV-1 and HIV-2 replication in vitro and, therefore, most probably they are no NNRTI's (Non-Nucleoside Reverse Transcriptase Inhibitors). The anti-HIV activity and the selectivity of these compounds are, however, too limited to perform extensive mode-of-action studies. The synthesis of new analogs of thiazolo-amino acid derivatives (carboxamide analogs 9b and 9c) may lead to the discovery of more potent and selective analogs that will allow the elucidation of their molecular mode-of-action.
Conclusion
In summary, in vitro anti-HIV screening led to the identification of the 1,3-thiazole backbone bearing amino acid derivatives 9b and 9c as new anti-HIV candidates and promising agents for further structural modification and pharmacological evaluation.
Experimental Section
Melting points are uncorrected and were measured on a Gallenkamp melting point apparatus (MP-D). Microanalytical data were obtained with a Euro Vector EA 3000 Elemental apparatus. NMR spectra were recorded on a Bruker 300 MHz NMR spectrometer. The multiplicities are abbreviated as br s = broad singlet, s = singlet, d = doublet, t = triplet, q = quartet, at = apparent triplet, ddd = doublet of doublets of doublets, qn = quintet. IR spectra were recorded on a Schimadzu Fourier transform infrared spectrophotometer model 270, using the ATR facility. EI-MS spectra were recorded on an Agilent technologies 6890N (GC) mass spectrometer with an inert selective detector 5973. TLC plates 60 F 254 were purchased from Merck.
Synthesis of 2-phenyl-1,3-thiazole-4-carbohydrazides 4a-i
A mixture of ethyl bromopyruvate (2) (1.5 mmol) and arylthioamide (1.5 mmol) in EtOH (25 mL) was refluxed for 8 h. After completion of the reaction (TLC), the mixture was concentrated, and water was added to the reaction mixture, followed by extraction with CH 2 Cl 2 (3 × 50 mL). The combined organic extracts were dried (Na 2 SO 4 ) and filtered, and the filtrate was evaporated to dryness. The crude esters 3a-i were used for the synthesis of carbohydrazides 4a-i, without further purification. To a solution of ethyl 2-aryl-1,3-thiazole-4-carboxylates 3a-i (1.3 mmol) in MeOH (25 mL) was added slowly 80 % hydrazine hydrate (2.6 mmol), and the reaction mixture was heated under reflux for 8-10 h. The progress of the reaction was monitored by TLC. After completion the mixture was concentrated in vacuo, followed by addition of cold water. The precipitated solid was filtered and recrystallized from aq. EtOH.
2-(4-Methylphenyl)-1,3-thiazole-4-carbohydrazide (4a)
Yield: 236 mg (78 %), m. p. 181 • C. R f = 0.69 (petroleum ether-acetone, 3 : 2). -IR (cm -1 ): ν max = 3400, 3284 (2 × NH stretch.), 1655 (C=O stretch.), 1649 (C=N stretch.), 1557 (NH bend. 
2-(4-Chlorophenyl)-1,3-thiazole-4-carbohydrazide (4d)
Yield
2-(4-Methoxyphenyl)-1,3-thiazole-4-carbohydrazide (4g)
2-(3-Methoxyphenyl)-1,3-thiazole-4-carbohydrazide (4h)
2-(2-Methoxyphenyl)-1,3-thiazole-4-carbohydrazide (4i)
Synthesis of N -(2-oxoindolin-3-ylidene)-2-aryl-1,3-thiazole-4-carbohydrazides 6a-i
Compound 4 (1.0 mmol) and isatin (5) (1.0 mmol) were dissolved in warm EtOH (25 mL) containing glacial HOAc (0.5 mL). The reaction mixture was refluxed for 6-8 h. On completion of the reaction (TLC), excess solvent was removed under reduced pressure, and the precipitate obtained on cooling was collected by filtration and recrystallized from a DMF-water mixture. 
N -(2-Oxoindolin-3-ylidene)-2-(4-methylphenyl)-1,3-thiazole-4-carbohydrazide (6a)
From
N -(2-Oxoindolin-3-ylidene)-2-(3-methylphenyl)-1,3-thiazole-4-carbohydrazide (6b)
N -(2-Oxoindolin-3-ylidene)-2-(3-chlorophenyl)-1,3-thiazole-4-carbohydrazide (6e)
Synthesis of 5-(2-(substituted-phenyl)-1,3-thiazol-4-yl)-1,3,4-oxadiazole-2-thiones 7a-i
To a mixture of hydrazide 4 (2.0 mmol) and KOH (2.4 mmol) in MeOH (30 mL) was added CS 2 (2.4 mmol) dropwise. The yellow solution obtained was refluxed till the evolution of hydrogen sulfide ceased (Pb(OAc) 4 test). After 3 h, the solution was cooled and filtered. The filtrate was poured into ice-cooled water and acidified with 6 N HCl to pH 3-4. The solid product obtained was filtered, dried (Na 2 SO 4 ) and recrystallized from CHCl 3 . 
5-[2-(4-
Methylphenyl
5-[2-(3-Methylphenyl)-1,3-thiazol-4-yl]-1,3,4-oxadiazole-2-thione (7b)
General preparation of carboxamido-thiazoles 9a-d
To a cold solution (∼ −5 • C) of 4f (507 mg, 2.0 mmol) in HOAc (14 mL), 1 N HCl (7 mL), and water (30 mL) was added a solution of NaNO 2 (172 mg, 2.5 mmol) in cold water (4 mL). After stirring at −5 • C for 15 min, a yellow syrup was formed. The azide was taken in cold ethyl acetate (30 mL), washed with a 3 % solution of NaHCO 3 , washed with water, and finally dried (Na 2 SO 4 ). A solution of amino acid methyl ester (2.33 mmol) in ethyl acetate (20 mL) containing 3.5 mL of Et 3 N was stirred at 0 • C for 20 min and filtered, and the filtrate was added to the acid solution. The mixture was kept at −5 • C for 12 h, then at 23 • C for another 12 h, followed by washing with 0.5 N HCl, water and a 3 % solution of NaHCO 3 , and finally dried (Na 2 SO 4 ). The solution was evaporated to dryness, and the residue was either an oil, purified on an SiO 2 column, or a solid, recrystallized from ethyl acetate-petroleum ether to give the desired products.
Methyl (2-(2-(4-chlorophenyl)thiazole)-4-carboxamido)-acetate (9a)
